WO2001051016A1 - Methode de traitement d'affections par amelioration de l'efficacite du systeme immunitaire humain - Google Patents

Methode de traitement d'affections par amelioration de l'efficacite du systeme immunitaire humain Download PDF

Info

Publication number
WO2001051016A1
WO2001051016A1 PCT/US2001/000714 US0100714W WO0151016A1 WO 2001051016 A1 WO2001051016 A1 WO 2001051016A1 US 0100714 W US0100714 W US 0100714W WO 0151016 A1 WO0151016 A1 WO 0151016A1
Authority
WO
WIPO (PCT)
Prior art keywords
ailment
compound
group
acid derivative
amino
Prior art date
Application number
PCT/US2001/000714
Other languages
English (en)
Inventor
Arthur Vanmoor
Original Assignee
Arthur Vanmoor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arthur Vanmoor filed Critical Arthur Vanmoor
Priority to AU27767/01A priority Critical patent/AU2776701A/en
Publication of WO2001051016A1 publication Critical patent/WO2001051016A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • This invention relates to a method of treating a person suffering an ailment with an agent that enhances the effectiveness of the human immune system to minimize the effects of the cancerous condition.
  • cancerous conditions are characterized by the uncontrolled growth of tissues commonly known as tumors .
  • Traditional attempts to mitigate the unfavorable effects of these have included surgical removal of tumors, administration of drugs that result in diminution of tumors, treatment with ionizing radiation to kill tumors, and all the possible combinations of these.
  • the MERCK MANUAL, 16 th edition, published 1992, at pages 1287 to 1292, which portion is here incorporated by reference, contains a table titled "Five Year Disease- free Survival Rates for Cancers Treated with Combined Therapies" listing the effectiveness in percent of various combination treatments against particular cancers at various stages.
  • Yoshimura et al U.S. Patent No. 5,576,351 disclosed treatment of an impaired human immune response by the administration of argmme or ornithme or mixtures thereof to humans suffering from impaired immune response or at risk of suffering impaired immune response. While it is stated that impaired immune response can be a secondary effect of such conditions as trauma or a debilitating disease such as cancer or infection with HIV virus, among others, there is no disclosure that any benefit m mitigating or relieving the effects of such conditions is obtained from administration of argmme or ornithme .
  • a method of treating an ailment a person m need of such treatment which comprises the administration to such person of at least one aliphatic sulfur compound.
  • the effectiveness of the aliphatic sulfur compound according to the invention is believed to accompany enhancement of the effectiveness of the person's immune system.
  • the aliphatic sulfur compound preferably includes a sulfur-methylene moiety such as -SCH 2 - or -SCH 2 CH-
  • the aliphatic sulfur compound also includes a carboxyl group, as -SCH 2 CH-0 2
  • the aliphatic sulfur compound is a sulfur-containing ammo-acid derivative of an ethyl sulfide having the formula (I)
  • A is hydrogen or a carboxymethylene -CH 2 C0 2 H group
  • B is hydrogen or an alkyl group having 1 to 3 carbon atoms
  • X is hydrogen, or an acyl group -CO-R in which R is an alkyl group having 1 to 3 carbon atoms, or a pharmaceutically acceptable salt of such compound.
  • the ethyl sulfide group -S-CH 2 CH- is believed to be responsible for the beneficial activity observed while the attached groups A, -NHX, and -C0 2 B assist in delivering the compound to the site within the human organism where the beneficial activity is exerted.
  • A is hydrogen
  • A, B, and X are not simultaneously hydrogen.
  • the present invention is based on the recognition that enhancing the effectiveness of the immune system in a person can be beneficial in augmenting the person's innate ability to resist the initiation and proliferation of a variety of ailments as well as their uncomfortable and potentially dangerous after-effects. Consequently, the quality of life is improved .
  • mega-nutrient doses of 2 to 20 grams of a compound or compounds of formula (I) can be administered to a victim up to eight times daily after signs of an ailment appear in order to diminish its extent and duration, continued until relief is noted, and tapered off to maintenance levels of about 10 grams daily or ceased entirely.
  • Such doses can also be administered in advance of or simultaneously with exposure to the agent or agents causing the ailment.
  • Doses can be administered in any convenient manner, as by oral administration in any of the usual dosage forms, such as tablets, capsules, solutions, and dispersions in liquid foods such as soups and fruit juices.
  • sterile solutions by direct injection into the bloodstream of the person to be treated, as well as by rectal suppositories.
  • cancerous conditions such as cancer of the prostate; headaches, particularly migraine; male impotence and insufficiency of stamina and endurance in physical activity; menstrual cramps in the human female; influenza; after-effects of alcohol ingestion including nausea, dizziness, lack of balance, and blurred vision; wrinkles of the facial skin and other effects of aging; bacterial infections; elevated blood levels of cholesterol; auto-immune deficiency disease (AIDS) ;
  • AIDS auto-immune deficiency disease
  • Alzheimer's disease Alzheimer's disease; arthritis; circulatory disorders including anemia, high blood pressure and hemophilia; metabolic imbalances leading to the unsightly deposition of body fat and cellulite; skin diseases such as exczema and psoriasis; respiratory diseases such as pneumonia, bronchitis, and asthma; diseases of internal organs such as stomach ulcers, kidney dysfunction, kidney stones, gall bladder insufficiency and hepatitis; allergies, diabetes, hair loss, hemorrhoids, and others.
  • a male with prostate enlargement diagnosed as a cancerous condition started a regimen of taking 10 grams of composition as in Example 1 with each meal for a total of 40 grams daily. He felt relief after a few weeks; after two months of this regimen the prostate was found to have shrunk to normal size, and after 4 months of this regimen cancer was no longer found to be present.
  • a 19 year old female with three cysts on her ovaries took 20 grams of composition as in Example 1 daily; after 4 weeks of treatment the cysts had disappeared.
  • Example 5 A 23 year old female with uterine cancer and endometrosis saw the cancer disappear after eight weeks of daily intake of 40 grams of composition as in Example 1.
  • Example 5 A 23 year old female with uterine cancer and endometrosis saw the cancer disappear after eight weeks of daily intake of 40 grams of composition as in Example 1.
  • a female volunteer with a long history of severe periodic migraine was given ten grams of composition comprising several compounds of formula (I) as soon as she felt the pain approaching, and repeated at intervals of 3-4 hours until the pa n ceased. She then reduced the dose to ten grams per day and has not had a recurrence of migraine.
  • composition comprising several compounds of formula (I) daily spread over the meals of each day and after four weeks of this treatment was achieving normal results, that is results comparable to those the same man achieved at age 30.
  • composition containing several compounds of formula (I) with each meal and at intervals of 2-3 hours between meals until the pain was diminished to no more than 10% of the original intensity. From then on the pam cleared without further intake of the composition.
  • Volunteers were tested to determine a threshold quantity of alcohol i.e. ounces of vodka given with a slice of bread on an empty stomach
  • a threshold quantity of alcohol i.e. ounces of vodka given with a slice of bread on an empty stomach
  • symptoms of impairment such as inability to walk 25 feet in a straight line within 30 minutes.
  • a third group received 40 groups of the same composition at the same time.
  • the average threshold quantity of alcohol for the members of the group receiving 40 grams of composition containing compounds of formula (I) was more than twice the average threshold quantity for the members of the control group .
  • a 41 year old male took 100 grams daily of composition containing compounds of formula (I) for a period of eight months . After this period he has been told by persons who saw him only before and after the treatment period that his appearance suggested that a face lift had been obtained. Also, comparison of photographs before and after the treatment period showed a younger appearance after the treatment with disappearance of wrinkles and softer texture of the skin. His overall energy level has increased to the level of ten years earlier. All this was achieved without changes in diet or physical activity.
  • Example 17 A male volunteer lost substantially all fat on areas of the body which became muscle tissue without exercise by taking 30 grams daily of composition including several compounds of formula I .
  • Example 17 A male volunteer lost substantially all fat on areas of the body which became muscle tissue without exercise by taking 30 grams daily of composition including several compounds of formula I .
  • a group of female volunteers took 30-50 grams per day of composition including compounds of formula I and noted disappearance of cellulite within a few weeks to a few months .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une méthode permettant de traiter les effets négatifs de différentes affections chez une personne nécessitant un tel traitement. Cette méthode consiste à améliorer l'efficacité du système immunitaire d'une personne par administration d'au moins un composé de soufre alipohatique, de préférence un dérivé d'acide aminé contenant du soufre représenté par la formule (I), ou d'un sel pharmaceutiquement acceptable de ce composé. Dans cette formule, A représente hydrogène ou un groupe carboxyméthylène -CH2CO2H, B représente hydrogène ou un groupe alkyle possédant 1 à 3 atomes de carbone, et X représente hydrogène, ou un groupe acyle -CO-R dans lequel R représente un groupe alkyle possédant 1 à 3 atomes de carbone.
PCT/US2001/000714 2000-01-07 2001-01-08 Methode de traitement d'affections par amelioration de l'efficacite du systeme immunitaire humain WO2001051016A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU27767/01A AU2776701A (en) 2000-01-07 2001-01-08 A method of treating an ailment by enhancing the effectiveness of the human immune system

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17486000P 2000-01-07 2000-01-07
US60/174,860 2000-01-07
US71765700A 2000-11-21 2000-11-21
US09/717,657 2000-11-21

Publications (1)

Publication Number Publication Date
WO2001051016A1 true WO2001051016A1 (fr) 2001-07-19

Family

ID=26870609

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/000714 WO2001051016A1 (fr) 2000-01-07 2001-01-08 Methode de traitement d'affections par amelioration de l'efficacite du systeme immunitaire humain

Country Status (2)

Country Link
AU (1) AU2776701A (fr)
WO (1) WO2001051016A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892852A (en) * 1972-06-15 1975-07-01 Rech Pharm Scientifiques Pharmaceutical compositions containing cysteine derivatives
US4496548A (en) * 1983-02-04 1985-01-29 Moldowan Mervin J Composition and method for reducing hangover
US5202354A (en) * 1986-02-18 1993-04-13 Takeda Chemical Industries, Ltd. Composition and method for reducing acetaldehyde toxicity
JPH06279397A (ja) * 1993-03-31 1994-10-04 Eisai Co Ltd アミノ酸系末梢神経障害改善剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892852A (en) * 1972-06-15 1975-07-01 Rech Pharm Scientifiques Pharmaceutical compositions containing cysteine derivatives
US4496548A (en) * 1983-02-04 1985-01-29 Moldowan Mervin J Composition and method for reducing hangover
US5202354A (en) * 1986-02-18 1993-04-13 Takeda Chemical Industries, Ltd. Composition and method for reducing acetaldehyde toxicity
JPH06279397A (ja) * 1993-03-31 1994-10-04 Eisai Co Ltd アミノ酸系末梢神経障害改善剤

Also Published As

Publication number Publication date
AU2776701A (en) 2001-07-24

Similar Documents

Publication Publication Date Title
Milton On giant urticaria
Finley Ellingwood American materia medica, therapeutics and pharmacognosy
US5945119A (en) Therapeutic preparations containing caesium ions
AU683145B2 (en) Methods for treating neurofibromatosis
WO2001051016A1 (fr) Methode de traitement d'affections par amelioration de l'efficacite du systeme immunitaire humain
CN115154564A (zh) 一种中药保健香囊配方
JP2748199B2 (ja) 気管支喘息発作の予防と治療貼付剤
Field Jr et al. Pellagra in the Average Population of the Northern States
US6525097B1 (en) Method of treating a cancerous condition by enhancing the effectiveness of the human immune system
RU2632443C1 (ru) Способ лечения билиарного сладжа у больных хроническим билиарнозависимым панкреатитом
US6642272B1 (en) Method of treating a male impotence condition
RU2076731C1 (ru) Средство и способ повышения неспецифической резистентности организма при заболеваниях внутренних органов
US6476072B1 (en) Method of treating menstrual pain by enhancing the effectiveness of the human immune system
US6476073B1 (en) Method of treating a hangover by enhancing the effectiveness of the human immune system
US6277883B1 (en) Method of treating male impotence by enhancing the effectiveness of the human immune system
US6479547B1 (en) Method of treating an infection by enhancing the effectiveness of the human immune system
Stannard Materia medica and philosophic theory in Aretaeus
RU2182006C2 (ru) Способ лечения ревматоидного артрита
US20040175411A1 (en) Method of treating influenza
RU2031652C1 (ru) Способ лечения половых расстройств при хроническом простатите
US20210137837A1 (en) Treatments using oxygen microbubbles and cannabidiol
Hutchison The elements of medical treatment
US20040162350A1 (en) Method of treating a non-cancerous disease of the male prostate
OCHSNER et al. The Use of Vitamin B, for the Relief of Pain in Varicose Ulcers
RU2131733C1 (ru) Способ ослабления и профилактики абстинентного синдрома и средство для его осуществления

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP